Inventor · disambiguated record
Daniel Zagury
Also filed as: ZAGURY DANIEL · ZAGURY DANIEL A
25 granted patents·7 pending applications·162 citations·filing 1992–2021
94Inventor score
Top patents by PatentIndex Score
32 records- 0187US6200575B1Non-toxic immunogens derived from a retroviral regulatory protein antibodies preparation process and pharmaceutical compositions comprising themNEOVACS·Filed 2000·Granted Mar 13, 2001·18 cites·28 claims
- 0286US10632186B1Vaccine to pathogenic immune activation cells during infections21C Bio·Filed 2019·Granted Apr 28, 2020·3 cites·19 claims
- 0384US7314629B2Non-immunosuppressive immunogenic or vaccine composition comprising a mutated E7 protein of the HPV-16 virusNEOVACS·Filed 2003·Granted Jan 1, 2008·15 cites·24 claims
- 0484US7022482B2Use of immunogenic immunosuppressive and/or angiogenic proteins which have been rendered inactive, process for their preparation and pharmaceutical or vaccinal usesNEOVACS·Filed 2003·Granted Apr 4, 2006·14 cites·15 claims
- 0581US8697047B2Stable immunogenic product comprising antigenic heterocomplexesLE BUANNEC HELENE·Filed 2011·Granted Apr 15, 2014·12 cites·9 claims
- 0681US6093405AInactive but immunogenic cytokines, pharmaceutical compositions containing same, and methods of treating homeostatic disorders associated with an overproduction of cytokinesNEOVACS·Filed 1992·Granted Jul 25, 2000·55 cites·12 claims
- 0778US6878370B1Chemically modified TNF-αNEOVACS·Filed 2000·Granted Apr 12, 2005·7 cites·7 claims
- 0872US7887811B2Method for preparing a stable immunogenic product comprising antigenic heterocomplexes of TNFα and a carrier proteinNEOVACS·Filed 2006·Granted Feb 15, 2011·2 cites·16 claims
- 0969US6132721ANon-Toxic immunogens derived from a retroviral regulatory protein, antibodies, preparation method therefor, and pharmaceutical compositions containing sameNEOVACS·Filed 1996·Granted Oct 17, 2000·20 cites·27 claims
- 1068US11957748B2Vaccine to pathogenic immune activation cells during infections21C Bio·Filed 2021·Granted Apr 16, 2024·0 cites·19 claims
- 1166US8101165B2Use of immunogens to treat or prevent, in malignant tumors, the immune or vascular disorders induced by extracellular factorsZAGURY JEAN FRANCOIS·Filed 2007·Granted Jan 24, 2012·0 cites·4 claims
- 1262US11077185B2Vaccine to pathogenic immune activation cells during infections21C Bio·Filed 2020·Granted Aug 3, 2021·0 cites·18 claims
- 1362US7351554B2Use of inactive immunosuppressive and/or angiogenic immunogenic proteins, for producing secretory IgA'sNEOVACS·Filed 2005·Granted Apr 1, 2008·0 cites·12 claims
- 1462US6455045B1Immunogenic compounds with in particular an anti-cytokine effect, preparation process, pharmaceutical compositions and kits containing themNEOVACS·Filed 1999·Granted Sep 24, 2002·13 cites·11 claims
- 1558US8679483B2High-yield method for the production of human antibodies blocking the biological activity of a human cytokineBIZZINI BERNARD·Filed 2004·Granted Mar 25, 2014·2 cites·20 claims
- 1656US7504479B2Use of immunogenic immunosuppressive and/or angiogenic proteins which have been rendered inactive, process for their preparation and pharmaceutical or vaccinal usesNEOVACS·Filed 2005·Granted Mar 17, 2009·0 cites·14 claims
- 1754US12024558B2Method of inhibiting HIV-1 viral rebound in a subject using interferon inhibitors and ART21C Bio·Filed 2020·Granted Jul 2, 2024·0 cites·18 claims
- 1854US2023323299A1Population of treg cells functionally committed to exert a regulatory activity and their use for adoptive therapyINSERM INSTITUT NAT DE LA SANTE ET DE LA RECHERCH MEDICALE·Filed 2021·Application pending·0 cites
- 1953US8372388B2Method for preparing a stable TNF-α vaccineNEOVACS·Filed 2005·Granted Feb 12, 2013·0 cites·20 claims
- 2053US7015016B2Use of inactivated immunosuppressive or angiogenic immunogenic proteins for producing secretory IgA'sNEOVACS·Filed 2000·Granted Mar 21, 2006·0 cites·6 claims
- 2151US7972603B2Stable immunogenic product comprising antigenic heterocomplexesNEOVACS·Filed 2003·Granted Jul 5, 2011·0 cites·12 claims
- 2251US2004028647A1Vaccines against cytokines and growth factors derived from malignant tumoursFiled 2001·Application pending·0 cites
- 2351US2022119766A1Ex vivo generation of gamma delta foxp3+ regulatory t cells and therapeutic uses thereofINST NAT SANTE RECH MED·Filed 2021·Application pending·0 cites
- 2450US2022018835A1Use of cd26 and cd39 as new phenotypic markers for assessing maturation of foxp3+ t cells and uses thereof for diagnostic purposesINST NAT SANTE RECH MED·Filed 2019·Application pending·0 cites
- 2548US2004185058A1Composite superimmunogen for bi-functional vaccine use for the treatment of illnesses associated with a stromal tissue disorderFiled 2002·Application pending·0 cites
- 2646US7208148B2Chemically modified cytokinesNEOVACS S A·Filed 2005·Granted Apr 24, 2007·0 cites·19 claims
- 2745US2006252075A1Method for monitoring anti-HIV treatment in HIV infected individualsNEOVACS·Filed 2006·Application pending·0 cites
- 2841US11365392B2Ex vivo generation of MHCII restricted CD4+ FOXP3+ regulatory T cells and therapeutic uses thereofINST NAT SANTE RECH MED·Filed 2017·Granted Jun 21, 2022·0 cites·3 claims
- 2940US11198851B2Ex vivo generation of γδ Foxp3+ regulatory T cells and therapeutic uses thereofINST NAT SANTE RECH MED·Filed 2017·Granted Dec 14, 2021·0 cites·4 claims
- 3034US2019167791A1Immunotherapeutic uses of ex vivo generated foxp3+ regulatory t cellsINST NAT SANTE RECH MED·Filed 2017·Application pending·0 cites
- 3124US7067246B1Method for determining prognosis of HIV infected individualsNEOVACS S A·Filed 1999·Granted Jun 27, 2006·0 cites·2 claims
- 3223US6228890B1Use of alicyclic diamines as immunomodulatorsNEOVACS·Filed 1996·Granted May 8, 2001·1 cites·14 claims
Join the waitlist — get patent alerts
Get an alert when Daniel Zagury files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →